[Skip to Content]
[Skip to Content Landing]
Views 395
Citations 0
Correction
August 2018

Changes to Wording and Descriptions Throughout Text

JAMA Intern Med. 2018;178(8):1144. doi:10.1001/jamainternmed.2018.4085

In the Invited Commentary “Reforming the 340B Drug Pricing Program: Tradeoffs Between Hospital and Manufacturer Revenues” by Coukell and Dickson,1 there were several inaccuracies throughout the text, specifically in paragraphs 5, 6, 7, and 9, owing to the authors’ review of an earlier version of the accompanying Research Letter, on which they based their commentary. A letter of explanation2 describes the changes. This article has been corrected online.

References
1.
Coukell  AJ, Dickson  S.  Reforming the 340B drug pricing program: tradeoffs between hospital and manufacturer revenues  [published online May 21, 2018].  JAMA Intern Med. doi:10.1001/jamainternmed.2018.2007PubMedGoogle Scholar
2.
Coukell  AJ, Dickson  S.  Revised version of Research Letter by Nikpay et al and associated changes for accompanying commentary.  JAMA Intern Med. doi:10.1001/jamainternmed.2018.4151Google Scholar
×